End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.017 AUD | +6.25% | +13.33% | -15.00% |
10/04 | Syntara Reaches 50% Recruitment in Phase 2 Trial for Bone Marrow Cancer Treatment | MT |
29/02 | Syntara Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Sales 2024 * | 11.6M 7.58M 632M | Sales 2025 * | 3.6M 2.35M 196M | Capitalization | 20.3M 13.26M 1.11B |
---|---|---|---|---|---|
Net income 2024 * | -8M -5.23M -436M | Net income 2025 * | -13M -8.49M -708M | EV / Sales 2024 * | 1.13 x |
Net cash position 2024 * | 7.2M 4.7M 392M | Net cash position 2025 * | 9.2M 6.01M 501M | EV / Sales 2025 * | 3.08 x |
P/E ratio 2024 * |
-1.55
x | P/E ratio 2025 * |
-1.89
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.57% |
Latest transcript on Syntara Limited
1 day | +6.25% | ||
1 week | +13.33% | ||
Current month | -19.05% | ||
1 month | -19.05% | ||
6 months | -48.48% | ||
Current year | -15.00% |
Managers | Title | Age | Since |
---|---|---|---|
Gary Phillips
CEO | Chief Executive Officer | 62 | 12/03/12 |
Director of Finance/CFO | 67 | 01/02/01 | |
Jana Baskar
CTO | Chief Tech/Sci/R&D Officer | - | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Phillips
CEO | Chief Executive Officer | 62 | 12/03/12 |
Director of Finance/CFO | 67 | 01/02/01 | |
Kathleen Metters
CHM | Chairman | 66 | 07/17/07 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 0.017 | +6.25% | 4,541 |
24/24/24 | 0.016 | -5.88% | 5,793,995 |
23/24/23 | 0.017 | 0.00% | 1,711,394 |
22/24/22 | 0.017 | +13.33% | 1,315,731 |
19/24/19 | 0.015 | -6.25% | 1,574,918 |
End-of-day quote Australian S.E., April 26, 2024
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-15.00% | 13.24M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- SNT Stock